Close

News

OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

OSE Immunotherapeutics SA announced that the company has entered into a worldwide license option agreement with Servier, an independent international pharmaceutical company, for the development and commercialization of OSE Immunotherapeutics’ Effi-7, an antagonist of the interleukin-7 receptor. ...

Saneca Pharma Expands R&D Capabilities

Contract development and manufacturing organization (CDMO) Saneca Pharma is driving forward with new research and development initiatives for the manufacture of active pharmaceutical ingredients (APIs) following a €1.5 million grant from the Slovak Ministry of Education, Science, Research and...

Cerevance launched with new technology, drug portfolio and $36m in cash to tackle brain diseases 

Takeda Pharmaceutical Company Limited and Lightstone Ventures announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created in...

Sun Pharma launches first branded ophthalmic product, BromSite™, in USA

Sun Pharma announced the launch of BromSite™ (bromfenac ophthalmic solution) 0.075% in the US market.A nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.  ...

CeMAT, Industrial Automation and Motion Drive & Automation to redefine manufacturing technology in India

WIN INDIA 2016, India’s leading industrial and engineering trade fair will bring together 3 key industrial trade fairs - CeMAT INDIA, Industrial Automation INDIA (IA India) and Motion Drive & Automation INDIA (MDA India). The events...

CPhI & P-MEC India gets bigger with an exclusive ‘India Pharma Week 2016’

UBM India, India's leading exhibition organizer, is all set to host CPhI & P-MEC India 2016, one of the world’s leading pharmaceutical networking event in Mumbai. In its tenth anniversary, the expo is slated to transform...

Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

Biothera Pharmaceuticals Inc will present new preclinical data that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »